Search Results - brian+brooks

2 Results

Sort By:

TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A

Summary: The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A. Description of Technology: Oculocutaneous albinism (OCA) is a genetically heterogeneous congenital disorder characterized by decreased or absent pigmentation in the hair,...

Published: 12/23/2024 | Inventor(s): Brian Brooks, Aman George

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Rare / Neglected Diseases, TherapeuticArea > Ophthalmology, TherapeuticArea > Ear, Nose, & Throat, Collaboration Sought > Licensing

Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation

Abstract: Albinism (also called achromia, achromasia, or achromatosis) is a congenital disorder characterized by the complete or partial absence of pigment in the skin, hair and eyes due to absence or defect in any one of a number of proteins involved in the production of melanin. Certain forms of albinism are known to be due to mutations in tyrosine...

Published: 12/6/2024 | Inventor(s): Brian Brooks, William Gahl, David Adams

Keywords(s): achromasia, achromatosis, achromia, Albinism, Nitisinone, Ocular disorders, pigmentation

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology